Overview
Background
A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.
Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Qualifications
- Bachelor (Honours) of Medicine, University of Zurich
- Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
- Doctoral (Research), University of Zurich
- Professional Doctorate, University of Zurich
- Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists
Research impacts
Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.
Works
Search Professor Simone M Goldinger’s works on UQ eSpace
2013
Conference Publication
Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Goldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2013
Conference Publication
The genetic landscape of clinical resistance to RAF inhibition in melanoma
Van Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2013
Conference Publication
The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
Heinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL.
2013
Journal Article
Current treatment of melanoma of the skin = Aktuelle therapie des melanoms der haut
Dummer, Reinhard, Goldinger, Simone M., Sailer, Eva and French, Lars E. (2013). Current treatment of melanoma of the skin = Aktuelle therapie des melanoms der haut. Therapeutische Umschau, 67 (9), 447-452. doi: 10.1024/0040-5930/a000078
2013
Journal Article
RASopathic Skin Eruptions during Vemurafenib Therapy
Rinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721
2013
Journal Article
Melanoma immunotherapy: historical precedents, recent successes and future prospects
Raaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162
2013
Journal Article
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745
2012
Journal Article
Therapeutic approaches in melanoma - A paradigm for personalized medicine = Melanomtherapie - Ein paradigma für die personalized medicine
Dummer, Reinhard, Goldinger, Simone, Rinderknecht, J., Eggmann, N., Felderer, L., Braun, R. and French, L. E. (2012). Therapeutic approaches in melanoma - A paradigm for personalized medicine = Melanomtherapie - Ein paradigma für die personalized medicine. Praxis, 101 (15), 955-959. doi: 10.1024/1661-8157/a001005
2012
Journal Article
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patients
Goldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361
2012
Journal Article
From chemotherapy to targeted treatment
Dummer, R., Rozati, S., Eggmann, N., Rinderknecht, J. and Goldinger, S. M. (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23, 101-103. doi: 10.1093/annonc/mds308
2012
Conference Publication
OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)
Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS.
2012
Journal Article
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition
Zimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660
2012
Conference Publication
Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)
Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
2012
Book Chapter
Cutaneous drug eruptions associated with the use of new oncological drugs
Belloni, Benedetta, Schönewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous drug eruptions associated with the use of new oncological drugs. Adverse cutaneous drug eruptions. (pp. 191-202) edited by Lars E. French. Basel, Switzerland: S. Karger. doi: 10.1159/000335632
2012
Journal Article
Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs
Dummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370
2012
Journal Article
Ultraviolet A and Photosensitivity during Vemurafenib Therapy
Dummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752
2012
Journal Article
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126
2011
Conference Publication
Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL.
2011
Conference Publication
Inhibition of the MEK-kinase pathway in advanced melanoma
Dummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER.
2011
Conference Publication
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases
Dummer, R., Rinderknecht, J., Goldinger, S. M., Wagner, I., Mitchell, L., Veronese, M. L., Nick, S., Hilfiker, P. and Gobbi, S. (2011). An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8548
Supervision
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Skin micro-bio-tox: understanding the skin toxicity associated with immune checkpoint inhibitors
Associate Advisor
Other advisors: Dr Janin Chandra, Professor Kiarash Khosrotehrani
-
Doctor Philosophy
Novel genomic predictors of survival in thin and thick melanomas
Associate Advisor
Other advisors: Professor Kiarash Khosrotehrani, Associate Professor Mitchell Stark
Media
Enquiries
For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team: